Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Tumors
NCT07056777Phase 2Recruiting
- Sponsor
- Doer Bio
- Start
- Mar 2025
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of DR30206 in gastrointestinal cancer, sponsored by Doer Bio. Started Mar 2025; status: recruiting.
02
Drugs
DR30206
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT07056777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07056777.